Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
- 1 big thing: Congress takes on PBMs
- Here comes Humira competition
- Humira Competitors Don’t Guarantee Lower Patient Drug Costs
- The State of Biosimilars: What to Watch
- ‘The Price of Business’: Discussing the Latest Inflation Report
- Alex Brill Interviewed on the Future of the Adalimumab Market
- Taking Stock of the Humira Biosimilars Market
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
- Analyzing the Build It in America Act: Proposals for Business Tax Reform
